Compare Capital One Financial Corp. (COF) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capital One Financial Corp. vs Moderna, Inc. — how do they compare? Capital One Financial Corp. trades at $206.38 (market cap $126.46B), while Moderna, Inc. trades at $67.3 (market cap $26.76B). The key difference: Capital One Financial Corp. is far larger — about 4.7× Moderna, Inc.'s market cap, and Capital One Financial Corp. pays a 1.56% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| COF | MRNA | |
|---|---|---|
Market Cap | $126.46B | $26.76B |
Sector | Financials | Health |
52-Week High | $257.94 | $81.80 |
52-Week Low | $176.10 | $22.36 |
Dividend Yield | 1.56% | — |
Enterprise Value | — | $22.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $203.02, up 0.74% with a bullish technical signal from moving averages. The stock shows mixed earnings performance with recent misses but strong revenue growth to $53.43B in 2025. Analyst consensus remains positive with a $252.40 price target and 62.5% buy ratings, while the Discover integration presents significant expansion opportunities amid credit risk concerns.
COF offers potential upside from current levels with Wall Street optimism around the Discover acquisition, though investors face headwinds from rising delinquencies and margin compression. The stock's valuation at 62.44 P/E appears elevated relative to modest ROE of 3.34%, requiring careful monitoring of integration execution and credit quality trends.
Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.
While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
